🎯 Retatrutide's TRIUMPH-2:
18.8% Weight Loss

The obesity-drug arms race has a new frontrunner. At the EASD meeting in Milan on September 29, 2026, Eli Lilly unveiled full Phase 3 results for retatrutide — a once-weekly triple agonist targeting GIP, GLP-1, and glucagon receptors — and simultaneously published the TRIUMPH-2 trial in The Lancet. In 1,152 adults with type 2 diabetes and obesity, the drug delivered weight loss that eclipses everything on the market.

The dose-response curve is strikingly clean: 11.9% at 4 mg, 16.8% at 9 mg, and 18.8% at 12 mg — all massively ahead of placebo's 5.1%. Nearly half of participants on the top dose shed at least 20% of their body weight, and 31% lost 25% or more — territory that starts to overlap with bariatric surgery outcomes. By trial's end, 59.5% of the 12 mg group no longer met the clinical criteria for obesity at all.

The metabolic wins extended well beyond the scale. Glycemic control improved dramatically, with A1C dropping 1.4 to 1.6 percentage points across doses — a diabetes-management effect on par with dedicated glucose-lowering drugs. And two quality-of-life findings stood out: participants reported 73% less knee arthritis pain and experienced 60% fewer sleep-apnea events, underscoring how much of obesity's burden is mechanical as well as metabolic.

Tolerability looks familiar to anyone who has followed this drug class: gastrointestinal effects led the adverse-event list, with diarrhea in 34%, nausea in 28%, and vomiting in 16% of participants. Most events were mild-to-moderate and clustered during dose escalation — the standard trade-off profile for potent incretin therapies, and one clinicians have learned to manage.

With TRIUMPH-2 published and the broader TRIUMPH program advancing, Eli Lilly has signaled it plans to submit retatrutide to the FDA in early 2027. If approved, it would become the first triple-agonist obesity therapy — and, on these numbers, the most effective pharmacologic weight-loss option ever brought to regulators. The next questions are durability: whether the weight stays off, and what years of triple-receptor activation mean for the heart, bones, and muscle mass.